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Baker's Yeast Breeding and Engineering to Improve Biologics Manufacturing
Chris Finnis, Les Evans, Anne Henstra, David Harvey, Charlotte Smith, Alex Pritchard, Ed Louis
Contact: chris@phenotypeca.com Website: www.phenotypeca.com

The regulatory-friendly baker’s yeast Saccharomyces cerevisiae
has a bright future for cost reduction and improved access to
medicines, especially for lower and middle-income countries. It
has been used safely for biopharmaceutical manufacturing since
1987, although this work only used a limited number of closely
related strains. These were improved by chemical mutagenesis
and rational genome engineering for first-generation platforms,
producing biopharmaceuticals currently worth over $40
billion/year in market value.
Phenotypeca has developed a next-generation biologics
production platform using genetically diverse baker’s yeast from
different geographical and ecological niches1. Four parent strains
with around 100,000 segregating functional SNPs were
engineered for protease reduction, chaperone overexpression and
other modifications known to improve product yield and quality
during cGMP manufacturing of recombinant products. Advanced
multi-generational breeding2 produced libraries of approximately a
billion genetically distinct progeny for the intracellular production
or secretion of a range of recombinant proteins. These
populations contain industrially stable, exchangeable, high copy
number expression plasmids and consist of only yeast DNA plus a
codon-optimised synthetic gene of interest. Results for mCherry
and mCherry-tagged proteins, including SARS-CoV-2 antigens,
demonstrated that progeny populations contained phenotypes
better than the best parent and worse than the worst parent. High
throughput screening and selection workflows using flowcytometry and robotics systems have been developed to select
individuals with improved properties for robust manufacturing
processes.

Introduction
Production Strains: Since the original S. cerevisiae S288c
genome sequence was published in 1996, it has been has
revealed that strains used to develop first generation baker’s
yeast expression platforms were closely related to S288c and
W303, with mosaic genomes derived from the Wine/European
lineage (Figure 1)1, 3. Phenotypeca has similarly engineered
strain collections of this type (YPT strains) with modifications
known to improve product yield and quality during cGMP biologics
manufacturing.
Additionally, four parent strains, isolated from diverse
geographical and ecological niches which contain around 100,000
independently segregating naturally selected genomic SNPs,
were chosen as the basis for the generation of novel strains for
recombinant protein production. Haploid derivatives of these
strains lacking the natural 2-micron plasmid were prepared with
auxotrophic markers for breeding and expression plasmid
maintenance.
Derivatives were also produced with gene
disruptions and insertions to increase yield and quality during
recombinant protein production, e.g. to control proteolysis,
glycosylation, protein folding and mRNA levels.
All production strains are designed for cGMP biologics
manufacturing and simple regulatory approval, and are devoid of
antibiotic resistance markers, containing only S. cerevisiae DNA
plus a synthetic gene codon-optimised for the recombinant
product of interest.

Expression Plasmids: High-copy number episomal expression
plasmids based on the whole 2-micron plasmid were designed for
stable maintenance during industrial scale production. Plasmid
copy number is enhanced by complementary genome engineering
in the parental strains to elevate the transcript levels for the
recombinant product. Promoter, leader and terminator sequences
are selected from libraries for each recombinant protein of
interest. Recombinant protein production is repressed during
breeding and activated afterwards for selection of strains with
improved phenotypes from the diverse progeny generated.
Fluorescent protein tags, e.g. mCherry, were used to facilitate
selection during flow cytometry. Plasmids expressing mCherrytagged proteins can be exchanged for the final plasmids without
the mCherry-tag by growth in non-selective media and retransformation with the desired final expression plasmid.
Similarly, strains improved for one recombinant product can easily
be tested for new products.

Multi-Generational Breeding
Pair-wise crosses with parents of opposite mating-types were
performed for all four parents, with one parent strain transformed
to leucine prototrophy with an expression plasmid. Diploids were
sporulated and spores pooled for multi-generational crosses to
produce populations of approximately a billion progeny (Figure 2).
Auxotrophic markers ura3 and/or lys2, were used for
haploid/diploid selection. Final populations were induced for
recombinant protein expression and screened for product yield
and quality.
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Figure 2: Four diverse parental yeast strains are bred to generate
diverse populations for phenotypic screening.
Typical workflows (Figure 3) use flow cytometry followed by
individual strain phenotyping for feasibility studies (PhenoStart™),
strain optimisation (PhenoDev™) and process development
(PhenoFull™).

Intracellular Products: The mCherry fluorophore was used to
compare phenotypic diversity for recombinant protein production
between parental and progeny strains.
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Figure 6: Single cells were sorted for mCherry fluorescence using
a Beckman Coulter Astrios EQ cell sorter for expression analysis.
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Secreted Products: A range of SARS-CoV-2 spike protein
fragments were secreted with C-terminal mCherry tags using the
invertase leader sequence. Figure 6 shows flow cytometry
results for cell sorting of 4th generation progeny secreting a
SARS-CoV-2 Spike protein fragment (RBD 344-604) fusion.
Microtitre plate cultures for individuals selected for high mCherry
signal by flow cytometry were visibly red compared to individuals
with low mCherry signal.
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Figure 3: PhenoStart™ feasibility study and PhenoDev™ strain
optimisation workflows.

Figure 1: Phylogenetic tree diagram from the Saccharomyces
Genome Resequencing Project showing clean lineages in relation
to traditional laboratory strains1. A total of 235,127 SNPs, 14,051
indels and 38 new ORFs were identified among the five clean
lineages and mosaics strains. One individual representative from
each of the North American (NA), Sake (SA), West African (WA)
and Wine/European (WE) clean lineages was selected for
recombinant protein production and breeding. The Malaysian (M)
lineage was not used. All strains were compliant with the Nagoya
Protocol (UN Convention on Biological Diversity).

Figure 5: Comparison of S. cerevisiae parental and progeny strains
for intracellular mCherry production.

Figure 4 (right) shows the
phenotypic diversity for
intracellular mCherry
expression after breeding,
with a wide range of visible
differences in colony colour.
Typically, progeny better
than the best parent, and
worse than the worst
parent, are generated by
breeding.
Figure 5 shows a Box and Whisker Plot for mCherry fluorescence
from 24 colonies from each clean lineage parent and 192 colonies
for 3rd generation progeny. Colonies were randomly picked and
grown for 5-days in 0.5mL selective minimal media (30⁰C,
200rpm, 48-well microtitre plates with humidity control). mCherry
signal was measured with Tecan Infinite M1000 PRO plate reader.
Eight progeny (4.2%) had higher, and two (1.0%) had lower
mCherry levels than the highest and lowest parent colonies,
respectively. The parental average (broken red line) was
comparable to the progeny average.
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Figure 7 (above) shows expression analysis for the ACE2
receptor binding motif fragment (RBM 438-505)4 of SARS-CoV-2
Spike protein (7A) with a C-terminal mCherry-tag. SDS-PAGE
analysis indicated a substantial increase in secreted product yield
after breeding (RBM ) compared to the control (C) grown in a
BioLector Pro mini-bioreactor system (mp2-labs). A proteolytic
degradation product is apparent below the expected size for
RBM-mCherry (7B). Significant yield improvements after breeding
was also evident for mCherry levels from the whole culture and
supernatants for progeny strains producing RBM-mCherry (DH01
to DH03). Rational engineering of progenitor laboratory strain
YPT2 was performed to disrupt proteinase A (pep4) and an
aspartic protease (yps1), along with engineering to over-express
protein disulphide isomerase (PDI1) and increase plasmid copy
number. This also gave a large increase in product yield (from
strain YPT9) (7C).

Conclusion
• Yeast breeding generated progeny phenotypes better than the
best parent and worse than the worst parent.
• Combining yeast breeding with rational genome engineering
offers a powerful strategy for improving recombinant protein
production from S. cerevisiae.
• Phenotypic improvement of production strains promises
significant cost reductions for biologics production.
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